Nyxoah S.A. (NASDAQ:NYXH – Get Rating) was the recipient of a significant decline in short interest during the month of April. As of April 30th, there was short interest totalling 203,600 shares, a decline of 17.7% from the April 15th total of 247,400 shares. Approximately 2.1% of the shares of the company are sold short. Based on an average daily volume of 42,800 shares, the short-interest ratio is presently 4.8 days.
Wall Street Analyst Weigh In
Separately, Stifel Nicolaus lowered their target price on shares of Nyxoah from $19.00 to $16.00 and set a “buy” rating for the company in a research note on Thursday, March 23rd.
Nyxoah Stock Performance
Shares of NYXH opened at $7.95 on Monday. The firm has a 50-day moving average price of $7.54 and a 200 day moving average price of $6.17. The firm has a market capitalization of $198.30 million, a PE ratio of -6.31 and a beta of 1.42. The company has a quick ratio of 6.66, a current ratio of 6.72 and a debt-to-equity ratio of 0.09. Nyxoah has a 52-week low of $4.36 and a 52-week high of $14.80.
Institutional Trading of Nyxoah
A number of hedge funds have recently bought and sold shares of the company. Millennium Management LLC acquired a new position in Nyxoah in the fourth quarter worth approximately $51,000. ExodusPoint Capital Management LP acquired a new position in Nyxoah during the first quarter valued at approximately $97,000. Sei Investments Co. acquired a new position in Nyxoah during the second quarter valued at approximately $265,000. AXA S.A. grew its holdings in Nyxoah by 7.4% during the third quarter. AXA S.A. now owns 200,000 shares of the company’s stock valued at $1,260,000 after purchasing an additional 13,800 shares during the last quarter. Finally, Invesco Ltd. acquired a new position in Nyxoah during the first quarter valued at approximately $8,177,000. 11.47% of the stock is owned by hedge funds and other institutional investors.
Nyxoah Company Profile
Nyxoah SA, a medical technology company, focuses on the development and commercialization of solutions to treat sleep disordered breathing conditions. It offers Genio system, a CE-Marked, patient-centric, and hypoglossal neurostimulation therapy to treat moderate to severe obstructive sleep apnea. The company was incorporated in 2009 and is headquartered in Mont-Saint-Guibert, Belgium.
- Get a free copy of the StockNews.com research report on Nyxoah (NYXH)
- MarketBeat Week in Review – 5/8 – 5/12
- An Updraft Is Brewing For DraftKings
- PepsiCo Hits “Sweet Spot” For APAC Growth, Macros Agree
- High-Risk Mullen Automotive Continues To Build Momentum
- 3 Recession-Proof Stocks With Nice Dividends
Receive News & Ratings for Nyxoah Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Nyxoah and related companies with MarketBeat.com's FREE daily email newsletter.